MedPath

A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines

Phase 3
Conditions
Crow's Feet Lines
Interventions
Biological: HU-014
Biological: Botox Inj
Registration Number
NCT04081402
Lead Sponsor
Huons Co., Ltd.
Brief Summary

A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
290
Inclusion Criteria
  • Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
Exclusion Criteria
  • Volunteer who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
  • From screening, Subject who get a plastic Surgery within 48 Weeks
  • Subject who has skin disorder including infection and scar on injection site
  • Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.
  • Subject who takes a medication including anticoagulant, antithrombotic drug except low dose aspirin (below 325 mg/day)
  • Any condition that, in the view of the investigator, would interfere with study participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HU-014 InjHU-014-
Botox InjBotox Inj-
Primary Outcome Measures
NameTimeMethod
Change from Baseline of Crow's feet Lines improvement rate [Time Frame: Week 4]4 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Huons

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath